FOLH1 and neoplasm: The pattern of tumor PSMA expression should be evaluated per molecular imaging (preferred: 68 Ga/18F-PSMA PET; alternatively: 99mTc-PSMA SPECT/scintigraphy) together with a conventional comparator (e.g., CT, MRI, or bone scan) to rule out a relevant fraction of PSMA-negative lymph-node or visceral metastases or active/lytic bone lesions (strong recommendation) [91, 92].